Stephen Loughran
Family · Orange, CANPI 1801865308
Payments from drug & device makers
Across 226 payments — averaging $23.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$827
- GSK$531
- Lilly USA, LLC$519
- Amgen$480
- AbbVie$434
- AstraZeneca$322
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,21598%
- Education$872%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 42 | $827 |
| GSK | 24 | $531 |
| Lilly USA, LLC | 20 | $519 |
| Amgen | 9 | $480 |
| AbbVie | 19 | $434 |
| AstraZeneca | 16 | $322 |
| Abiomed | 8 | $295 |
| Regeneron Healthcare Solutions, Inc. | 9 | $289 |
| Merck | 11 | $266 |
| Novo Nordisk | 15 | $254 |
| Pfizer | 10 | $168 |
| United Therapeutics Corporation | 5 | $108 |
| Verona Pharma, Inc. | 4 | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $88 |
| Electromed, Inc. | 2 | $61 |
| Sanofi | 3 | $55 |
| Baxter Healthcare | 2 | $55 |
| Grifols USA, LLC | 2 | $40 |
| Paratek Pharmaceuticals, Inc. | 1 | $32 |
| Edwards Lifesciences | 2 | $31 |
| Exact Sciences | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Astellas Pharma US Inc | 1 | $28 |
| Actelion Pharmaceuticals US, Inc. | 1 | $28 |
| Phathom Pharmaceuticals, Inc. | 1 | $28 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Medtronic | 1 | $24 |
| Novartis | 1 | $23 |
| Nabriva Therapeutics, PLC | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $21 |
| Exeltis, USA Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,302 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 60 | $56,259 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $39,493 |
| OzempicSemaglutide | 26 | $35,299 |
| XareltoRivaroxaban | 25 | $29,397 |
| JardianceEmpagliflozin | 25 | $27,797 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $24,191 |
| TrulicityDulaglutide | 12 | $22,758 |
| MounjaroTirzepatide | 16 | $16,921 |
| JanuviaSitagliptin Phosphate | 15 | $15,156 |
| FarxigaDapagliflozin Propanediol | 11 | $14,946 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $10,549 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $7,798 |
| Atorvastatin Calcium | 518 | $5,714 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 168 | $5,404 |
| Levothyroxine Sodium | 357 | $5,157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $531 | $63,68473 claims |
| PfizerEliquis | $168 | $56,25960 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $519 | $39,67928 claims |
| Novo NordiskOzempic | $254 | $35,29926 claims |
| Johnson & JohnsonXarelto | $13 | $29,39725 claims |
| Boehringer IngelheimJardiance | $827 | $27,79725 claims |
| AstraZenecaFarxiga, Symbicort | $322 | $25,49530 claims |
| MerckJanuvia | $266 | $15,15615 claims |
| AbbVieSynthroid | $434 | $2,16527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Orange
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.